Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for September 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Activated Protein C Inhibitor Effective in Hemophilia A
FRIDAY, Sept. 30 (HealthDay News) -- Specific activated protein C (APC) inhibitor PNASN-1 significantly increases thrombin generation in the blood and plasma of individuals with congenital hemophilia A, with and without factor VIII (FVIII) deficiency, according to a study published online Sept. 15 in the Journal of Thrombosis and Haemostasis.
Abstract
Full Text (subscription or payment may be required)
Tamoxifen Use Tied to Diabetes Risk in Breast Cancer Survivors
FRIDAY, Sept. 30 (HealthDay News) -- Current tamoxifen therapy is associated with a significantly increased incidence of diabetes in older breast cancer survivors, according to a study published online Sept. 20 in Cancer.
Abstract
Full Text (subscription or payment may be required)
Doctors, Patients Identify Tacit Clues in Their Interactions
FRIDAY, Sept. 30 (HealthDay News) -- Both doctors and patients identify tacit clues as well as judgments based on these clues during video elicitation interviews of health maintenance examinations, according to a study published in the October issue of the Journal of Evaluation in Clinical Practice.
Abstract
Full Text (subscription or payment may be required)
High Risk of Salvage Transplant Failure Post Liver Resection
FRIDAY, Sept. 30 (HealthDay News) -- Initial liver resection (LR) in hepatocellular carcinoma (HCC) within Milan criteria (MC) is a valid treatment for patients with good liver function who develop recurrence within MC, but salvage transplantation (ST) has a high rate of failure for those with recurrence beyond MC, according to a study published online Sept. 19 in Hepatology.
Abstract
Full Text (subscription or payment may be required)
DNA Repair Capacity IDs Non-Small-Cell Lung Cancer Survival
WEDNESDAY, Sept. 28 (HealthDay News) -- DNA repair capacity (DRC) in peripheral lymphocytes is a significant, independent predictor of survival for patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Alternate Chromosome 17 Genes Detect True HER2 Status
WEDNESDAY, Sept. 28 (HealthDay News) -- For patients with breast cancer and polysomy 17, the true gene status of human epidermal growth factor receptor 2 (HER2) can be effectively determined by use of additional chromosome 17 fluorescent in situ hybridization (FISH) studies for Smith-Magenis syndrome (SMS), retinoic acid receptor alpha (RARA), and tumor protein p53 (TP53) genes, rather than the HER2-to-centromeric probe (CEP17) ratio, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Prostatic Intraepithelial Neoplasia IDs Lethal Cancer
WEDNESDAY, Sept. 28 (HealthDay News) -- Prostatic intraepithelial neoplasia (PIN) is prognostic of lethal prostate cancer (PCa), according to a study published online Sept. 27 in Cancer Epidemiology, Biomarkers & Prevention.
Abstract
Full Text (subscription or payment may be required)
Advanced Adenomas, CRCs More Prevalent in Men
TUESDAY, Sept. 27 (HealthDay News) -- For individuals older than 50 years, men have a significantly increased prevalence of adenomas, advanced adenomas (AAs), and carcinomas compared to women, according to a study published in the Sept. 28 issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Lower Cancer Fatalism Tied to Increased Cancer Screening
TUESDAY, Sept. 27 (HealthDay News) -- Better self-rated health and lower cancer fatalism are associated with greater participation in colorectal cancer (CRC) screening in England, and mediate the effect of socioeconomic status (SES) on fecal occult blood test (FOBt) uptake, according to a study published online Sept. 27 in Cancer Epidemiology, Biomarkers & Prevention.
Abstract
Full Text (subscription or payment may be required)
U.S. Docs Feel They Give More Patient Care Than Required
TUESDAY, Sept. 27 (HealthDay News) -- Many primary care physicians in the United States believe that their patients are receiving too much medical care, and that the pressure to do more than is necessary could be reduced by malpractice reform, adjusting financial incentives, and spending more time with patients, according to a study published in the Sept. 26 issue of the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
SF3B1 Mutations Linked to Myelodysplasia
TUESDAY, Sept. 27 (HealthDay News) -- Recurrent mutations in RNA splicing factor 3B, subunit 1 (SF3B1) are associated with myelodysplastic syndromes, and are more frequent in patients whose disease is characterized by the presence of ring sideroblasts, according to a study published online Sept. 26 in the New England Journal of Medicine to coincide with its presentation at the 2011 European Multidisciplinary Cancer Congress, held Sept. 23 to 27 in Stockholm, Sweden.
Abstract
Full Text (subscription or payment may be required)
More Information
ESR1 Expression Predicts Tamoxifen Benefit in Breast CA
TUESDAY, Sept. 27 (HealthDay News) -- Expression of ESR1 predicts tamoxifen benefit in estrogen receptor (ER)-positive breast cancer, with low levels of expression indicative of tamoxifen resistance, according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Cell of Origin Key in Relapsed B-Cell Lymphoma Prognosis
TUESDAY, Sept. 27 (HealthDay News) -- Patients with relapsed/refractory germinal center B (GCB)-like diffuse large B-cell lymphoma (DLBCL) have improved outcomes when treated with rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP), according to a study published online Sept. 26 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Editorial
Colorectal Cancer Subsite Risk Tied to Fruit/Vegetable Intake
TUESDAY, Sept. 27 (HealthDay News) -- The risk of colorectal cancer (CRC) associated with different fruit and vegetable (F/V) consumption varies depending on the tumor location within the large bowel, according to a study published online Sept. 26 in the Journal of the American Dietetic Association.
Full Text
Vitamin B12 Markers Tied to Cognition, Brain Volume
TUESDAY, Sept. 27 (HealthDay News) -- Serum vitamin B12 markers are associated with total brain volume and global cognitive function, with homocysteine affecting global cognitive performance and methylmalonate affecting total brain volume, according to a study published in the Sept. 27 issue of Neurology.
Abstract
Full Text (subscription or payment may be required)
Reasons for Referral to Specific Docs Differ Among Physicians
TUESDAY, Sept. 27 (HealthDay News) -- Primary care physicians (PCPs) and medical and surgical specialists differ in their reasons for selecting specific colleagues for referrals, with PCPs more concerned about physician communication and medical record sharing than specialists, according to a study published online Sept. 16 in the Journal of General Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Adjuvant Zoledronic Acid Not Beneficial in Breast Cancer
MONDAY, Sept. 26 (HealthDay News) -- For patients with early-stage breast cancer, the addition of zoledronic acid to standard adjuvant therapy does not offer any benefit for disease-free or overall survival, according to a study published in the New England Journal of Medicine to coincide with presentation at the 2011 European Multidisciplinary Cancer Congress, held from Sept. 23 to 27 in Stockholm, Sweden.
Abstract
Full Text
Soliris Approval Expanded to Include Rare Blood Disorder
FRIDAY, Sept. 23 (HealthDay News) -- Soliris (eculizumab) has been approved by the U.S. Food and Drug Administration as the first drug to treat atypical hemolytic uremic syndrome (aHUS), a rare blood disease that may trigger kidney failure, stroke or death.
more
Many Cushing Syndrome-EAS Tumors Found in Chest Cavity
FRIDAY, Sept. 23 (HealthDay News) -- For patients with Cushing syndrome (CS) secondary to ectopic adrenocorticotropic hormone (ACTH) secretion (EAS) who attend a comprehensive cancer center, nearly 50 percent have tumors in the chest cavity, notably bronchial carcinoid and small-cell lung cancer, according to a study published in the Oct. 1 issue of Cancer.
Abstract
Full Text (subscription or payment may be required)
Glucagon-Like Peptide-1 Therapy Ups Pancreatitis Risk
FRIDAY, Sept. 23 (HealthDay News) -- The use of exenatide and sitagliptin for type 2 diabetes is associated with a higher odds ratio of pancreatitis and increased reports of pancreatic cancer, according to a study published in the July issue of Gastroenterology.
Abstract
Full Text
Editorial
Stereotactic Radiosurgery Reasonable for Brain Mets
FRIDAY, Sept. 23 (HealthDay News) -- Salvage stereotactic radiosurgery (SRS) is a reasonable treatment for breast cancer brain metastases, with a median overall survival (OS) of more than nine months, according to a study published online Sept. 14 in Cancer.
Abstract
Full Text (subscription or payment may be required)
Serum Amino Acids Are Potential Biomarkers for Renal Cell Cancer
FRIDAY, Sept. 23 (HealthDay News) -- The levels of certain serum amino acids are significantly different in patients with renal cell carcinoma and show potential as biomarkers with predictive value for tumor recurrence and overall survival, according to a study published in the October issue of The Journal of Urology.
Abstract
Full Text (subscription or payment may be required)
Racial Discrimination Tied to RBC Oxidative Stress Levels
THURSDAY, Sept. 22 (HealthDay News) -- Self-reported racial discrimination is significantly associated with red blood cell (RBC) oxidative stress, with the association remaining statistically significant for African-Americans but not whites, after stratifying by race, according to a study published online Sept. 13 in the International Journal of Behavioral Medicine.
Abstract
Full Text
Soft Tissue Sarcoma Therapy Limb Salvage Rate 81 Percent
WEDNESDAY, Sept. 21 (HealthDay News) -- Tumor necrosis factor-α (TNF) and melphalan-based isolated limb perfusion (TM-ILP) therapy has a limb salvage rate of 81 percent in patients with locally advanced extremity soft tissue sarcomas (STSs) who would have otherwise undergone amputation, according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Mortality Up in Hospitals With More Minority Trauma Patients
WEDNESDAY, Sept. 21 (HealthDay News) -- The odds of in-hospital mortality for trauma patients are associated with the proportion of minority patients in the hospital, according to a study published online Sept. 19 in the Archives of Surgery.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Progression-Free Survival Not Tied to R-CHOP Dose Density
TUESDAY, Sept. 20 (HealthDay News) -- There is no significant difference in progression-free survival (PFS) for patients with indolent B-cell lymphoma treated with rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) along with granulocyte colony-stimulating factor (G-CSF) every three weeks (R-CHOP-21) or every two weeks (R-CHOP-14), according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Abstract
Full Text
Editorial
Model Predicts Erectile Function After Prostate Cancer Therapy
TUESDAY, Sept. 20 (HealthDay News) -- Erectile function two years after prostate cancer treatment can be predicted based on patient and treatment characteristics, according to a study published in the Sept. 21 issue of the Journal of the American Medical Association.
Abstract
Full Text
Editorial (subscription or payment may be required)
Tasquinimod Ups Castration-Resistant Prostate CA Survival
TUESDAY, Sept. 20 (HealthDay News) -- In men with castration-resistant prostate cancer (CRPC), treatment with tasquinimod (TASQ) significantly delays disease progression and improves progression-free survival (PFS) with an acceptable adverse event (AE) profile, according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Young Cancer Patients Have Low Clinical Trial Participation
TUESDAY, Sept. 20 (HealthDay News) -- Participation in clinical trials is low among adolescent and young adult (AYA) patients with cancer, with uninsured, older patients, or those treated by nonpediatric oncologists less likely to participate, according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Prolia Approval Expanded to Fracture Prevention in Cancer
MONDAY, Sept. 19 (HealthDay News) -- The U.S. Food and Drug Administration has expanded approval for the Amgen bone-building drug Prolia (denosumab) to include prostate cancer or breast cancer patients who are taking certain hormonal therapies.
more
Work Intensity Similar Across Physician Specialties
MONDAY, Sept. 19 (HealthDay News) -- The level of physician work intensity appears to be similar among specialties, with variations in the specific dimensions of stress, physical demands, performance, and temporal demand, according to a study published online Sept. 3 in Medical Care.
Abstract
Full Text (subscription or payment may be required)
Racial Disparities in Radical Prostatectomy Decreasing
MONDAY, Sept. 19 (HealthDay News) -- The racial disparity in the utilization rates of minimally invasive radical prostatectomy (MIRP) in the United States is decreasing, according to a study published online Sept. 6 in Cancer.
Abstract
Full Text (subscription or payment may be required)
Liver X Receptor Agonist Ups Glioblastoma Cell Death
FRIDAY, Sept. 16 (HealthDay News) -- Liver X receptor (LXR) agonists cause inducible degrader of low-density lipoprotein receptor (LDLR)(IDOL)-mediated LDLR degradation and elevated expression of the ABCA1 cholesterol efflux transporter, which promotes cell death in a glioblastoma model, according to an experimental study published online Sept. 15 in Cancer Discovery.
Abstract
Full Text (subscription or payment may be required)
Optimal CRC Screening Varies With Age, Family History
FRIDAY, Sept. 16 (HealthDay News) -- The optimal colonoscopy screening strategy for individuals with colorectal cancer (CRC) varies considerably with the number of affected first-degree relatives and their age at diagnosis, according to a study published in the Sept. 15 issue of Cancer.
Abstract
Full Text (subscription or payment may be required)
Anti-Nausea Drug May Lead to Dangerous Heart Rhythms
THURSDAY, Sept. 15 (HealthDay News) -- Zofran (ondansetron), used to prevent nausea in patients receiving cancer treatment, is undergoing an ongoing safety review and labeling change by the U.S. Food and Drug Administration because it may cause potentially fatal changes in heart rhythm, according to a Sept. 15 FDA safety alert.
More Information
CDC Finds That Lung Cancer Incidence Is Beginning to Fall
THURSDAY, Sept. 15 (HealthDay News) -- The prevalence of lung cancer in the United States is beginning to decrease for women and has decreased substantially for men in the last decade, most rapidly in states with fewer smokers, according to research published in the Sept. 16 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
Full Text
Global Rates of Breast, Cervical Cancer Up Over Last 20 Years
THURSDAY, Sept. 15 (HealthDay News) -- The global incidence of breast and cervical cancer increased from 1980 to 2010, with breast cancer mortality rates increasing and cervical cancer mortality rates decreasing during the same period, according to a study published online Sept. 15 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Tissue Factor Pathway Inhibitor Levels Up in Women With MI
THURSDAY, Sept. 15 (HealthDay News) -- Young women with myocardial infarction (MI) have higher tissue factor pathway inhibitor (TFPI) levels in comparison to those without MI, with increased TFPI activities and activated protein C (APC)-sensitivity correlating with MI, according to a study published online Sept. 5 in the Journal of Thrombosis and Haemostasis.
Abstract
Full Text (subscription or payment may be required)
Long-Term Nonaspirin NSAID Use Ups Renal Cell Cancer Risk
WEDNESDAY, Sept. 14 (HealthDay News) -- Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), but not aspirin and acetaminophen, is associated with an increased risk of renal cell cancer (RCC), with increased duration of use correlated with an elevated risk, according to a study published in the Sept. 12 issue of the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Mammography Screening Ups Breast Cancer Surgery Rates
WEDNESDAY, Sept. 14 (HealthDay News) -- The annual rate of breast surgery increased significantly from 1993-1995 to 2005-2008 for women in Norway aged 50 to 69 years who were invited to undergo mammography screening, according to a study published online Sept. 13 in BMJ.
Abstract
Full Text
Many Mistakenly Believe FDA OKs Only Safe, Effective Drugs
WEDNESDAY, Sept. 14 (HealthDay News) -- A considerable proportion of the U.S. public mistakenly believes that the U.S. Food and Drug Administration approves only effective and safe drugs, but providing consumer explanations can lead to better drug choices, according to a study published in the Sept. 12 issue of the Archives of Internal Medicine.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Sorafenib Plus DEB-TACE Safe, Tolerated in Unresectable HCC
WEDNESDAY, Sept. 14 (HealthDay News) -- In patients with unresectable hepatocellular carcinoma (HCC), combined treatment with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) and sorafenib is well tolerated and safe, according to a study published online Sept. 12 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Editorial
Number of Lymph Nodes Tested for Colon CA Up 1988 to 2008
TUESDAY, Sept. 13 (HealthDay News) -- For patients treated surgically for colon cancer, the number of lymph nodes evaluated increased from 1988 to 2008; however, there was no significant increase in lymph node positivity during the same period, according to a study published in the Sept. 14 issue of the Journal of the American Medical Association.
Abstract
Full Text
Editorial (subscription or payment may be required)
Dyslipidemia Ups Neuritic Plaque Risk in Alzheimer's
TUESDAY, Sept. 13 (HealthDay News) -- An abnormal lipid profile with high levels of total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDLC), and low-density lipoprotein cholesterol (LDLC) is significantly associated with neuritic plaque (NP)-type Alzheimer's disease (AD) pathology in a general Japanese cohort, according to a study published in the Sept. 13 issue of Neurology.
Abstract
Full Text (subscription or payment may be required)
Current Smoking Tied to Higher Risk of Hodgkin's Lymphoma
TUESDAY, Sept. 13 (HealthDay News) -- Current cigarette smoking is associated with an increased risk of developing Hodgkin's lymphoma (HL), with an elevated risk for men and older individuals, which increases with intensity and duration of smoking, according to a meta-analysis published online Sept. 12 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Venlafaxine, Clonidine Reduce Hot Flashes in Breast Cancer
TUESDAY, Sept. 13 (HealthDay News) -- Venlafaxine and clonidine effectively manage hot flashes in patients with breast cancer, with hot flash scores reducing more immediately with venlafaxine than clonidine, and reducing more significantly with clonidine during week 12 of treatment than with venlafaxine, according to a study published online Sept. 12 in the Journal of Clinical Oncology.
Abstract
Full Text (subscription or payment may be required)
Editorial
Ureteral Access Sheaths Safe in Urothelial Carcinoma
MONDAY, Sept. 12 (HealthDay News) -- Ureteral access sheaths (UASs) are safe for use in the diagnosis and treatment of upper tract urothelial carcinoma (UTUC), facilitate acquisition of multiple biopsy specimens adequate for histopathologic evaluation, and minimize the need for repeat diagnostic procedures, according to a study published in the September issue of Urology.
Abstract
Full Text (subscription or payment may be required)
Earlier Cancer Onset in Second Generation BRCA Carriers
MONDAY, Sept. 12 (HealthDay News) -- Women who are carriers of BRCA mutations for breast or ovarian cancer are more likely to be diagnosed with cancer at an earlier age than members of the previous generation, according to a study published online Sept. 12 in Cancer.
Abstract
Full Text (subscription or payment may be required)
TNF Inhibitors for RA Do Not Increase Malignancy Risk
MONDAY, Sept. 12 (HealthDay News) -- Treatment of rheumatoid arthritis (RA) with tumor necrosis factor inhibitors (TNFi) does not increase risk of malignancy, including lymphoma, but it may increase the risk of non-melanoma skin cancer and melanoma, according to a meta-analysis published online Sept. 1 in the Annals of Rheumatic Diseases.
Abstract
Full Text (subscription or payment may be required)
Cultured Red Blood Cells Can Survive in Vivo in Humans
FRIDAY, Sept. 9 (HealthDay News) -- Red blood cells (RBC) cultured in vitro survive in vivo with a half-life comparable to native RBC, and retain their quality and functionality, according to a study published online Sept. 1 in Blood.
Abstract
Full Text (subscription or payment may be required)
Alternative Lengthening of Telomeres ID'd in Most Cancers
FRIDAY, Sept. 9 (HealthDay News) -- The prevalence of the telomerase-independent telomere maintenance mechanism, known as alternative lengthening of telomeres (ALT), is 3.73 percent across all cancer subtypes, according to a study published online Sept. 2 in The American Journal of Pathology.
Abstract
Full Text (subscription or payment may be required)
Cytology Detects Proportion of Cervical Cancer Recurrence
THURSDAY, Sept. 8 (HealthDay News) -- Liquid-based cytology detects cervical cancer recurrence in about one-third of patients treated for cervical cancer; and, in the absence of any visible lesions, colposcopy is not indicated for follow-up of patients with atypical squamous cells of uncertain significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL), unless abnormalities persist, according to a study published in the September issue of Obstetrics & Gynecology.
Abstract
Full Text (subscription or payment may be required)
HPPH-Photodynamic Therapy Safe in Precancerous Barrett's
THURSDAY, Sept. 8 (HealthDay News) -- Photodynamic therapy (PDT) with 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) is safe with promising efficacy in precancerous lesions associated with Barrett's esophagus, according to a study published in the September issue of Lasers in Surgery and Medicine.
Abstract
Full Text (subscription or payment may be required)
Comparative Efficacy Proposed for European Drug Approval
WEDNESDAY, Sept. 7 (HealthDay News) -- New drugs should be compared with existing treatments instead of placebo before their approval in Europe, according to a report published online Sept. 6 in the BMJ.
Abstract
Full Text (subscription or payment may be required)
Malaria Predisposes Kenyan Children to Bacteremia
WEDNESDAY, Sept. 7 (HealthDay News) -- Malaria strongly predisposes children to the development of bacteremia in Kenya, according to a study published online Sept. 7 in The Lancet.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Medical Students Show Racial, Cultural Patient Preference
WEDNESDAY, Sept. 7 (HealthDay News) -- Medical students may have a preferential bias toward whites and wealthier patients, but this does not appear to influence their clinical decision making or physician-patient interactions, according to a study published in the Sept. 7 medical education-themed issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Odds of Board Certification Vary in New Doctors
WEDNESDAY, Sept. 7 (HealthDay News) -- Certification of recent U.S. medical school graduates by the American Board of Medical Specialties (ABMS) varies across specialties by educational and demographic factors, according to a study published in the Sept. 7 medical education-themed issue of the Journal of the American Medical Association.
Abstract
Full Text (subscription or payment may be required)
Age, Tumor Size Ups Mortality for Most Women With Breast CA
WEDNESDAY, Sept. 7 (HealthDay News) -- For most women with breast cancer who are node negative and have estrogen receptor-positive and/or progesterone receptor-positive tumors, mortality risk is associated with age and tumor size, according to a study published online Aug. 31 in the Journal of the National Cancer Institute.
Abstract
Full Text (subscription or payment may be required)
Editorial
Many Hospital Staff Uniforms Contaminated With Bacteria
WEDNESDAY, Sept. 7 (HealthDay News) -- More than 60 percent of hospital staff uniforms are contaminated with potentially pathogenic bacteria, including drug-resistant species, according to a study published in the September issue of the American Journal of Infection Control.
Abstract
Full Text (subscription or payment may be required)
Cases of Transfusion-Linked Babesiosis in U.S. Described
TUESDAY, Sept. 6 (HealthDay News) -- From 1979 to 2009, 159 Babesia microti (B. microti) transfusion-associated cases of Babesiosis were identified in the United States, and occurrence was not limited by season or region, according to a study published online Sept. 5 in the Annals of Internal Medicine.
Abstract
Full Text
Photodynamic Therapy Cost-Effective for High-Grade CIN
FRIDAY, Sept. 2 (HealthDay News) -- In Germany, photodynamic therapy (PDT) using hexylaminolevulinate (HAL) has the potential to be a more cost-effective treatment for high-grade cervical intraepithelial neoplasia (CIN) than conization, and implementation of PDT may reduce perinatal morbidity and associated costs, according to a study published in the September issue of Lasers in Surgery and Medicine.
Abstract
Full Text (subscription or payment may be required)
Researchers Ponder 9/11 Health Impact a Decade Later
FRIDAY, Sept. 2 (HealthDay News) -- It may be too early to tell how much of an impact the World Trade Center (WTC) disaster and its immediate aftermath had on those exposed, but cancer, death, mental and physical disorders, and spirometric abnormalities appear higher in people who received greater levels of exposure, according to three studies published in the 9/11-themed Sept. 3 issue of The Lancet.
Abstract - Zeig-Owens
Full Text (subscription or payment may be required)
Abstract - Jordan
Full Text (subscription or payment may be required)
Abstract - Wisnivesky
Full Text (subscription or payment may be required)
MRI Tumor Assessment Predicts Rectal Cancer Survival
FRIDAY, Sept. 2 (HealthDay News) -- Magnetic resonance imaging (MRI) assessment of tumor regression grade (TRG) and circumferential resection margin (CRM) can be used to predict survival for good and poor responders in rectal cancer, according to a study published online Aug. 29 in the Journal of Clinical Oncology.
Abstract
Full Text
Success With Valproic Acid for Glioblastoma With TMZ Therapy
THURSDAY, Sept. 1 (HealthDay News) -- Patients with glioblastoma requiring antiepileptic drugs (AEDs) during temozolomide (TMZ)-based chemoradiotherapy have an improved overall survival with valproic acid (VPA) than with an enzyme-inducing antiepileptic drug (EIAED), according to a study published online Aug. 31 in Neurology.
Abstract
Full Text
Editorial (subscription or payment may be required)
IDH1 Mutations Identify Ganglioglioma Prognosis
THURSDAY, Sept. 1 (HealthDay News) -- The presence of mutations in isocitrate dehydrogenase 1 (IDH1) can be used to identify gangliogliomas which are significantly associated with a greater risk of recurrence, malignant transformation, and death, according to a study published in the September issue of Brain Pathology.
Abstract
Full Text (subscription or payment may be required)
Novel Viral Therapy May Benefit Cancer Patients
THURSDAY, Sept. 1 (HealthDay News) -- A novel, intravenously-delivered viral therapy appears to selectively infect and replicate in tumor cells without invading and harming healthy tissue in individuals with advanced cancer, according to a study published online Aug. 31 in Nature.
Abstract
Full Text (subscription or payment may be required)
NPe6 May Beat Photofrin Photodynamic Therapy in Lung CA
THURSDAY, Sept. 1 (HealthDay News) -- NPe6-photodynamic therapy (PDT) is a better treatment for patients with lung cancer than photofrin-PDT, and the efficacy of PDT may improve based on individual expression status of the anti-apoptotic protein Bcl-2 and breast cancer-resistant protein (BCRP), according to a study published online Aug. 23 in Lasers in Surgery and Medicine.
Abstract
Full Text (subscription or payment may be required)
